BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 7475301)

  • 1. Serum G-CSF levels in patients undergoing G-CSF/chemotherapy mobilized peripheral stem cell harvest and predictors of neutrophil and platelet recovery.
    Maharaj D; Gómez-Marín O; Lewis-Ximenez LL; Riley R; Albarracín C
    Leukemia; 1995 Oct; 9 Suppl 1():S113-7. PubMed ID: 7475301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.
    Hohaus S; Goldschmidt H; Ehrhardt R; Haas R
    Exp Hematol; 1993 Apr; 21(4):508-14. PubMed ID: 7681782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose granulocyte colony-stimulating factor enables the efficient collection of peripheral blood stem cells after disease-oriented, conventional-dose chemotherapy for breast cancer, malignant lymphoma and germ cell tumor.
    Kohno A; Takeyama K; Narabayashi M; Okamoto R; Adachi I; Tobinai K; Shimoyama M
    Bone Marrow Transplant; 1995 Jan; 15(1):49-54. PubMed ID: 7538002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer.
    Ho AD; Glück S; Germond C; Sinoff C; Dietz G; Maruyama M; Corringham RE
    Leukemia; 1993 Nov; 7(11):1738-46. PubMed ID: 7901454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
    Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields.
    Sautois B; Fraipont V; Baudoux E; Fassotte MF; Hermanne JP; Jérusalem G; Bours V; Bosquée L; Schaaf-Lafontaine N; Paulus JM; Sondag D; Fillet G; Beguin Y
    Haematologica; 1999 Apr; 84(4):342-9. PubMed ID: 10190949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.
    Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K
    Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support.
    Papadopoulos KP; Ayello J; Tugulea S; Heitjan DF; Williams C; Reiss RF; Vahdat LT; Suciu-Foca N; Antman KH; Hesdorffer CS
    J Hematother; 1997 Feb; 6(1):61-8. PubMed ID: 9112219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization.
    Passos-Coelho JL; Braine HG; Davis JM; Huelskamp AM; Schepers KG; Ohly K; Clarke B; Wright SK; Noga SJ; Davidson NE
    J Clin Oncol; 1995 Mar; 13(3):705-14. PubMed ID: 7533827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells .
    Haas R; Murea S
    Cytokines Mol Ther; 1995 Dec; 1(4):249-70. PubMed ID: 9384679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
    Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
    Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients.
    Filip S; Vanásek J; Bláha M; Mericka P; Vávrová J; Podzimek K
    Neoplasma; 1999; 46(3):166-72. PubMed ID: 10613592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer.
    Schwella N; Beyer J; Schwaner I; Heuft HG; Rick O; Huhn D; Serke S; Siegert W
    J Clin Oncol; 1996 Apr; 14(4):1114-21. PubMed ID: 8648365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
    Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
    Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation.
    Kiss JE; Rybka WB; Winkelstein A; deMagalhaes-Silverman M; Lister J; D'Andrea P; Ball ED
    Bone Marrow Transplant; 1997 Feb; 19(4):303-10. PubMed ID: 9051238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
    Brugger W; Birken R; Bertz H; Hecht T; Pressler K; Frisch J; Schulz G; Mertelsmann R; Kanz L
    Br J Haematol; 1993 Jul; 84(3):402-7. PubMed ID: 7692928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens.
    Cesana C; Regazzi E; Garau D; Caramatti C; Mangoni L; Rizzoli V
    Haematologica; 1999 Sep; 84(9):771-8. PubMed ID: 10477448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitation of primitive and lineage-committed progenitors in mobilized peripheral blood for prediction of platelet recovery post autologous transplant.
    Hogge DE; Lambie K; Sutherland HJ; Benny WB; Dalal B; Currie C; Barnett MJ; Eaves AC; Eaves CJ
    Bone Marrow Transplant; 2000 Mar; 25(6):589-98. PubMed ID: 10734292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood stem cell mobilization with chemotherapy and granulocyte-colony stimulating factor in patients with hematological malignancies.
    Watanabe S; Mukaiyama T; Ogawa Y; Kawada H; Ichikawa Y
    Tokai J Exp Clin Med; 1994 Dec; 19(3-6):143-55. PubMed ID: 7570686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.